Clinical trial
Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma
NCT00057343 · Biogen, Industry · Terminated
Key facts
| NCT number | NCT00057343 |
|---|---|
| Title | Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma |
| Official title | A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL |
| Lead sponsor | Biogen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Zevalin (ibritumomab tiuxetan), Rituxan (rituximab) |
| Enrollment | 400 |
| Start date | Mar 1, 2003 |
| First posted | Apr 1, 2003 |
| Last update posted | Sep 12, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: